Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA exonuclease 1 homolog (REXO1) is a eukaryotic enzyme with predicted 3'-to-5' exonuclease activity, implicated mainly in rRNA 3'-end processing and found in the nuclear body[1][3][4]. REXO1 encodes a large protein (1221 amino acids), containing an exonuclease domain, and can bind Elongin, a transcription elongation factor[5]. While REXO1 does not appear to directly affect transcription elongation in vitro, it is recognized as a marker for embryonic stem cells and is expressed in both embryonic and multipotent stem cells as well as certain cancer lines[1][5]. Its presence is tightly regulated at the epigenetic level and lost upon cell differentiation, demarcating pluripotent from lineage-primed states[1]. There are no known small-molecule drugs or therapies that directly target REXO1, nor are there established safety concerns specific to its targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA exonuclease 1 homolog (REXO1).